NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed the link of the audio recording of the Earnings call for the quarter and nine months ended December 31, 2023, conducted on February 9, 2024
Neuland Laboratories Ltd. Results Earnings Call for Q3FY24
Conference Call with Neuland Laboratories Ltd. Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript. NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Credit Rating
Announcement under Regulation 30 (LODR) - Upgrade of Credit Rating Q3FY24 Quarterly & 9MFY24 Result Announced for Neuland Laboratories Ltd.
Pharmaceuticals company Neuland Laboratories announced Q3FY24 & 9MFY24 results: Q3FY24 vs Q4FY23: Total Income: Rs 394.9 crore, showing a growth of 46.2% compared to Q3FY23. EBITDA: Rs 122.7 crore, increased significantly by 123.5% from Q3FY23. EBITDA Margin: 31.1%, improved by 1080 basis points (bps) from Q3FY23. PAT: Rs 80.7 crore, showing a substantial growth of 165.1% compared to Q3FY23. PAT Margin: 20.4%, increased by 910 bps from Q3FY23. EPS (Basic): Rs 62.9, reflecting a growth of 165.1% compared to Q3FY23. 9MFY24 vs 9MFY23: Total Income: Rs 1,180.8 crore, increased significantly by 50.3% compared to 9MFY23. EBITDA: Rs 362.3 crore, showing a substantial growth of 136.4% compared to 9MFY23. EBITDA Margin: 30.7%, improved by 1120 bps from 9MFY23. PAT: Rs 232.0 crore, showing a substantial growth of 195.1% compared to 9MFY23. PAT Margin: 19.6%, increased by 960 bps from 9MFY23. EPS (Basic): Rs 180.8, reflecting a growth of 195.1% compared to 9MFY23. Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We are pleased to report another quarter of strong YoY topline growth of 46% to Rs 395 crore. The EBITDA margin of 31.1% is a factor of the business mix as well as improved operational leverage. Even as we see this as a validation of Neuland’s business model, we are focused on continuously improving operations across the company. We are investing both on infrastructure and our people so that we can deliver on our long-term plans.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw healthy growth led by commercial as well as projects close to commercialization. The increasing interest from customers with exciting pipelines establishes Neuland’s reputation as a well regarded CDMO. As the quality and size of our business grows, we are gaining a better visibility of our future and planning accordingly.” Result PDF NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on the Financial results of the Company for the quarter and nine months ended December 31, 2023 NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Financial Results of the Company for the quarter and nine months ended December 31, 2023 NEULAND LABORATORIES LTD. - 524558 - Board Meeting Outcome for Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2023
Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2023 NEULAND LABORATORIES LTD. - 524558 - Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2023
Unaudited Financial Results of the Company for the Quarter and Nine months ended December 31, 2023 NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings call Intimation Q3 FY24
